What does this study add?

• Dapagliflozin reduced the risk of worsening HF and CV death by 18% in patients with HF and mildly reduced EF and in patients with HF and preserved EF, in the DELIVER trial.⁶
• Dapagliflozin’s benefit was consistent across the range of left ventricular (LV) EF.⁶
• In general, adverse event rates increased with worsening glycaemic status, both categorically and also using HbA1c as a continuous variable.⁶
• Dapagliflozin improved HF outcomes in patients with HF and mildly reduced EF and in patients with HF and preserved EF across the spectra of both EF and glycaemia.⁶